Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver Metastasis

NCT02631564 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2015-12-16

No results posted yet for this study

Summary

The purpose of this study is to observe whether hepatic infusion by oxaliplatin, irinotecan and raltitrexed with or without embolization by lipiodol or microspheres are effective in the treatment of refratory liver metastasis from colorectal cancer.

Conditions

  • Colon Cancer Liver Metastasis

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Bo Zhou, M.D,Ph.D · Shanghai Zhongshan Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-06-30
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02631564 on ClinicalTrials.gov